Arcturus Therapeutics (ARCT) Gets a Hold From Leerink Partners
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $60
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $45
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $60
Arcturus Therapeutics Analyst Ratings
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Optimistic Buy Rating for Arcturus Therapeutics Amid Promising Cystic Fibrosis Treatment Developments
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $58
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $68
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $48
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $50 to $140
Arcturus Therapeutics Price Target Cut to $50.00/Share From $58.00 by Wells Fargo
Arcturus Therapeutics Is Maintained at Overweight by Wells Fargo
Arcturus Therapeutics Analyst Ratings
Positive Outlook for Arcturus Therapeutics: Strong Vaccine Sales and Promising Cystic Fibrosis Program Drive Buy Rating
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $50